Evidence map›Paper›PMID 31451486›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2020

Lin Xie, Masayuki Hanyu, Masayuki Fujinaga, Yiding Zhang, Kuan Hu, Katsuyuki Minegishi, Cuiping Jiang, Fuki Kurosawa, Yukie Morokoshi, Huizi Keiko Li and 3 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 26 citations in OpenAlex.

  1. AnEuropean journal of nuclear medicine and molecular imaging · 2025
    Article
  2. Radiopharmaceuticals and their applications in medicine.Signal transduction and targeted therapy · 2025
    Review
  3. Review
  4. Review
  5. ACell reports. Medicine · 2023
    Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Lin XieDepartment of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
Masayuki HanyuDepartment of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
Masayuki FujinagaDepartment of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
Yiding ZhangDepartment of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan zhang.ming-rong@qst.go.jp.
Kuan HuDepartment of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
Katsuyuki MinegishiDepartment of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
Cuiping JiangDepartment of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
Fuki KurosawaDepartment of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
Yukie MorokoshiDepartment of Charged Particle Therapy Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan; and.
Huizi Keiko LiDepartment of Charged Particle Therapy Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan; and.
Sumitaka HasegawaDepartment of Charged Particle Therapy Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan; and.
Kotaro NagatsuDepartment of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
Ming-Rong ZhangDepartment of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan zhang.ming-rong@qst.go.jp.
National Institutes for Quantum and Radiological Science and Technology · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeted radionuclide therapy (TRT) targeting oncoproteins facilitates the delivery of therapeutic radionuclides to tumor tissues with high precision. Herein, we developed 2 new radiopharmaceuticals, 4-

Indexed as

AnimalsAstatineBenzamidesIodine RadioisotopesMelanoma, ExperimentalMiceRadiochemistryReceptors, Metabotropic GlutamateSafetyTissue DistributionTumor Protein, Translationally-Controlled 1AstatineAstatine-211benzamideBenzamidesIodine-131Iodine Radioisotopesmetabotropic glutamate receptor type 1Receptors, Metabotropic GlutamateTpt1 protein, mouseTumor Protein, Translationally-Controlled 1melanomametabotropic glutamate receptor 1 (mGluR1)oncoproteinsmall-molecule radiopharmaceuticaltargeted radionuclide therapy (TRT)

Identifiers

PMID31451486
PMCPMC8801953
OpenAlexW2970692578

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.